AR093645A1 - Una formulacion estabilizada de pemetrexed - Google Patents

Una formulacion estabilizada de pemetrexed

Info

Publication number
AR093645A1
AR093645A1 ARP130104389A ARP130104389A AR093645A1 AR 093645 A1 AR093645 A1 AR 093645A1 AR P130104389 A ARP130104389 A AR P130104389A AR P130104389 A ARP130104389 A AR P130104389A AR 093645 A1 AR093645 A1 AR 093645A1
Authority
AR
Argentina
Prior art keywords
pemetrexed
stabilized formulation
stabilized
formulation
acetylcysteine
Prior art date
Application number
ARP130104389A
Other languages
English (en)
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48665454&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR093645(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Publication of AR093645A1 publication Critical patent/AR093645A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)

Abstract

Formulación estabilizada de pemetrexed y más en particular, a una formulación estabilizada de pemetrexed que comprende acetilcisteína como antioxidante y una sal de citrato como tampón.
ARP130104389A 2012-11-29 2013-11-28 Una formulacion estabilizada de pemetrexed AR093645A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120137375A KR101260636B1 (ko) 2012-11-29 2012-11-29 안정화된 페메트렉시드 제제

Publications (1)

Publication Number Publication Date
AR093645A1 true AR093645A1 (es) 2015-06-17

Family

ID=48665454

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104389A AR093645A1 (es) 2012-11-29 2013-11-28 Una formulacion estabilizada de pemetrexed

Country Status (16)

Country Link
US (1) US9265832B2 (es)
EP (1) EP2925325B1 (es)
JP (1) JP5934448B2 (es)
KR (1) KR101260636B1 (es)
CN (1) CN104812392B (es)
AR (1) AR093645A1 (es)
BR (1) BR112015012460B1 (es)
CL (1) CL2015001461A1 (es)
ES (1) ES2656901T3 (es)
HK (1) HK1212224A1 (es)
JO (1) JOP20130342B1 (es)
MX (1) MX355461B (es)
PH (1) PH12015500900B1 (es)
RU (1) RU2620341C2 (es)
TW (1) TWI498128B (es)
WO (1) WO2014084651A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012010774A1 (de) * 2012-05-31 2013-12-05 Stada Arzneimittel Ag Pharmazeutische Pemetrexed-Lösung
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
PL3040074T3 (pl) 2013-10-03 2019-03-29 Fujifilm Corporation Preparat iniekcyjny i sposób jego wytwarzania
JP6120766B2 (ja) * 2013-12-27 2017-04-26 富士フイルム株式会社 注射液製剤及びその製造方法
KR101703980B1 (ko) 2013-12-30 2017-02-08 주식회사 삼양바이오팜 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법
ES2686870T3 (es) * 2014-03-28 2018-10-22 Fujifilm Corporation Preparación de inyección y método para producirla
GB201418555D0 (en) * 2014-10-16 2014-12-03 Teva Gmbh Pemetrexed formulations
KR101770605B1 (ko) * 2014-11-17 2017-08-23 동아에스티 주식회사 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물
KR101919436B1 (ko) 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법
KR101693675B1 (ko) 2015-12-14 2017-01-06 주식회사 종근당 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
JP6837895B2 (ja) * 2017-04-04 2021-03-03 日本化薬株式会社 医薬品溶液製剤の製造方法
US20200246263A1 (en) * 2017-08-29 2020-08-06 Fresenius Kabi Oncology Limited Stable liquid compositions of pemetrexed
KR102040034B1 (ko) 2017-12-13 2019-11-05 주식회사 아이큐어비앤피 페메트렉시드를 포함하는 경구용 약학 조성물 및 이의 제조방법
US10966982B2 (en) 2018-11-20 2021-04-06 Cipla Limited Stable pharmaceutical formulations of pemetrexed
US20230201203A1 (en) * 2020-04-09 2023-06-29 Emphascience, Inc. Methods of treatment using antifolates and pharmaceutical formulations comprising antifolates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
CA2032695A1 (en) 1989-12-20 1991-06-21 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
TR200401436T4 (tr) * 2000-02-04 2004-07-21 Eli Lilly And Company Monotiyogliserol, L-sistem veya tiyoglikolik asitle birlikte pemetrexed içeren farmasötik bileşim
US6686365B2 (en) * 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
KR100774366B1 (ko) 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
CH697021A5 (de) * 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
DK1767219T3 (da) 2004-03-10 2010-05-10 Shimoda Biotech Pty Ltd Stabile injicerbare diclofenac-sammensætninger
KR101083230B1 (ko) * 2006-08-14 2011-11-11 시코르, 인크. 페메트렉세드 이산의 동결 건조된 약학적 허용염의 제조 방법
EP2072518A1 (en) * 2007-12-23 2009-06-24 Sun Pharma Advanced Research Company Limited Stable Amorphous Form of Pemextred Disodium
JP2013540104A (ja) 2010-07-28 2013-10-31 イーグル・ファーマシューティカルズ・インコーポレーテッド 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
DE102012010774A1 (de) * 2012-05-31 2013-12-05 Stada Arzneimittel Ag Pharmazeutische Pemetrexed-Lösung
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제

Also Published As

Publication number Publication date
HK1212224A1 (en) 2016-06-10
US9265832B2 (en) 2016-02-23
CL2015001461A1 (es) 2015-10-23
JOP20130342B1 (ar) 2021-08-17
CN104812392A (zh) 2015-07-29
US20150297724A1 (en) 2015-10-22
MX2015006325A (es) 2016-02-25
BR112015012460A2 (es) 2017-08-22
ES2656901T3 (es) 2018-02-28
RU2015122023A (ru) 2017-01-10
MX355461B (es) 2018-04-19
EP2925325B1 (en) 2017-11-01
TW201434493A (zh) 2014-09-16
WO2014084651A1 (en) 2014-06-05
TWI498128B (zh) 2015-09-01
PH12015500900A1 (en) 2015-07-06
EP2925325A1 (en) 2015-10-07
RU2620341C2 (ru) 2017-05-24
CN104812392B (zh) 2017-05-17
KR101260636B1 (ko) 2013-05-13
JP2016500099A (ja) 2016-01-07
BR112015012460B1 (pt) 2022-04-05
PH12015500900B1 (en) 2015-07-06
EP2925325A4 (en) 2016-07-13
JP5934448B2 (ja) 2016-06-15

Similar Documents

Publication Publication Date Title
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
UY34885A (es) Proteínas de unión anti-mesotelina
UY34772A (es) ?una formulación de fármaco de liberación retardada?.
ECSP14013302A (es) Composiciones de yodo-povidona estable
PL2897984T3 (pl) Wodna kompozycja emulsyjna nadtlenku organicznego
CA2875305C (en) Fbxo3 inhibitors
CO2017007316A2 (es) Formulación farmacéutica
MX2015006986A (es) Solucion de trombina y metodos de uso de esta.
CR20120521A (es) Combinaciones de principios activos
BR112013027222A2 (pt) composição de liberação prolongada que contém peptídeos como ingrediente ativo
UY34807A (es) Derivados monocíclicos de heteroarilcicloalquil- diamina
UY4242Q (es) Mesa
EP2968158A4 (en) Rodent hepadnavirus cores with reduced carrier-specific antigenicity
EP2978434A4 (en) COMPOSITIONS, FORMULATIONS AND METHODS FOR BIO-BALANCING THE PH OF ISOTONIC SALT SOLUTION AND STERILE HYPERTONIC SOLUTES
BR112013027488A2 (pt) Combinações de substâncias ativas e formulações cosméticas
UA62955U (ru) Применение экстракта коры осины в качестве средства адаптогенного действия
UA79010U (ru) Применение n -стеароилэтаноламина в качестве вещества с активным антигриппозным действием
NZ708737A (en) Thrombin solution and methods of use thereof
UA65458U (ru) Пиридилгидразоны, которые проявляют антиоксидантную активность
TWD160310S (zh) 風鏡
UY4225Q (es) Casquillo pentagonal para eslingas
CL2011003000S1 (es) Mesa .
TN2011000399A1 (fr) دراجة كهربائية ذات شحن الي
CL2012000641S1 (es) Lavamanos.

Legal Events

Date Code Title Description
FC Refusal